Merz concludes enrolment in Phase III Xeomin trials for migraine

​

Merz Therapeutics has concluded patient enrolment in MINT-C and MINT-E, two global Phase III clinical trials assessing Xeomin for adult migraine prevention.

The post Merz concludes enrolment in Phase III Xeomin trials for migraine appeared first on Hospital Management.

 

Back to the Featured Stories

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.